On CNBC's "Mad Money Lightning Round," Jim Cramer said AbbVie Inc. (NYSE:ABBV) is doing "very, very well." However, he added that Abbott Laboratories (NYSE:ABT) remains his favorite in the group ...
BMO Capital analyst Evan Seigerman maintains $AbbVie (ABBV.US)$ with a buy rating, and adjusts the target price from $214 to $220. According to TipRanks data, the ...